Patients treated with Dimethyl fumarate are at risk for opportunistic infections with and without severe lymphocytopenia
Patients receiving Dimethyl fumarate ( DMF ) are at risk for opportunistic infections even without severe lymphocytopenia.
An additional patient with progressive multifocal leukoencephalopathy ( PML ) and the immune reconstitution inflammatory syndrome after DMF treatment with only a modest case of lymphocytopenia was reported recently.
Because the number of patients treated with Dimethyl fumarate has increased rapidly since the approval of delayed-release Dimethyl fumarate as first-line treatment for relapsing–remitting multiple sclerosis, progressive multifocal leukoencephalopathy or other opportunistic infections may develop in more patients.
Safety monitoring of patients treated with Dimethyl fumarate is crucial, because opportunistic infections can occur in patients without severe lymphocytopenia.
Further studies concerning safety monitoring and new methods for identification of patients at risk are therefore urgently needed.
Researchers have reported a 23-year-old male patient with psoriasis who was treated with DMF ( Fagron ). After 2 months of treatment, fever, skin lesions unrelated to psoriasis, and cervical, axillary, and inguinal lymphadenopathy developed.
Histopathological findings were consistent with herpesvirus infection. Polymerase-chain-reaction testing confirmed the diagnosis of varicella–zoster virus ( VZV ) infection; serologic testing was positive for IgM antibodies to varicella–zoster virus, but there was no IgG response.
The patient had no documented lymphocytopenia. Because his medical history mentioned chickenpox during childhood, researchers made the diagnosis of generalized VZV infection.
The DMF treatment may have reactivated the VZV infection in this patient, because the infection developed 2 months after the initiation of treatment, he never received ultraviolet-light therapy, and he did not use topical glucocorticoids.
This case suggests that patients treated with DMF may have an increased risk of viral infection, even in the absence of lymphocytopenia.
Dimethyl fumarate has been shown to reduce specific lymphocyte subpopulations even when total lymphocyte counts exceed 500 cells per cubic millimeter. It appears, therefore, that in spite of normal lymphocyte counts, patients receiving Dimethyl fumarate may be at risk for infections.
A human herpesvirus 8–related Kaposi's sarcoma developed in a patient with psoriasis who was receiving DMF treatment and who had normal total lymphocyte counts but low counts of CD4+ and CD8+ lymphocytes.
Thus, it may be important to assess cell counts of specific lymphocyte subsets during treatment with Dimethyl fumarate. Measurement of intracellular ATP concentrations in CD4+ lymphocytes has been suggested to monitor for decreased CD4+-mediated immunity during treatment with Dimethyl fumarate.
Low levels of intracellular ATP in CD4+ lymphocytes were detected in a patient in whom DMF-related progressive multifocal leukoencephalopathy developed. ( Xagena )
Source: The New England Journal of Medicine, 2015
Jyseleca for the treatment of adults with moderate to severe active rheumatoid arthritis - European Commission approved
The European Commission ( EC ) has granted marketing authorization for Jyseleca ( Filgotinib 200 mg and 100 mg tablets...
SELECT-CHOICE trial: Upadacitinib more effective than Abatacept in patients with moderate to severe active rheumatoid arthritis and prior inadequate response or intolerance to bDMARD
New phase 3 data from the SELECT-CHOICE clinical trial have shown that Upadacitinib ( Rinvoq ), 15 mg, once daily,...
Upadacitinib, a JAK1-selective inhibitor, for adults with moderately to severely active rheumatoid arthritis who fail to adequately respond or are intolerant to Methotrexate
Upadacitinib ( Rinvoq ) was developed as a JAK1-selective inhibitor by exploiting differences in the non-conserved domains outside the active...
Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2...
A meta-analysis of phase III, randomised, placebo-controlled trials has assessed the benefits and harms of Pregabalin ( Lyrica ) in...
FDA has approved Keytruda for adult and pediatric patients with classical Hodgkin lymphoma refractory to treatment, or who have relapsed after three or more prior lines of therapy
The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), the anti-PD-1 ( programmed death...
European Commission has approved Empliciti for the treatment of multiple myeloma in adult patients who have received at least one prior therapy
The European Commission has approved Empliciti ( Elotuzumab ) for the treatment of multiple myeloma as combination therapy with Revlimid...
Heavily pre-treated patients with relapsed or refractory classical Hodgkin lymphoma: Pembrolizumab, as a monotherapy, shows overall response rates of 73 to 83%, with complete response rates of 27 to 30%
The findings from KEYNOTE-087, the phase 2 study investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, as...
Relapsing-remitting multiple sclerosis: Tysabri in highly active patients with inadequate response to prior therapy
The Committee of Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has...
Moderate to severe systemic lupus erythematosus: Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, improves symptoms in multiple organ domains including skin and joints
Anifrolumab is an investigational, fully human monoclonal antibody that binds to subunit 1 of the type I IFN receptor, inhibiting...